Dupixent® (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis

Friday, June 19, 2020 1 min read

Key Takeaway: Dupixent® (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis

Full Press Release Details

Dupixent® (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis.